AADI (Aadi Bioscience Inc) Prakiraan volume dodolan

Aadi Bioscience (AADI) aims to secure a leadership position in the treatment of rare sarcomas, outpacing major industry players. The company is engaged in a fierce battle for patents and scientific talent. Demand for its products remains independent of economic conditions, ensuring stability. The company's future sales indicator demonstrates the current capital trajectory, where the value of 0.03 reflects this status.

AADI - Volume dodolan sing dikarepake perusahaan Aadi Bioscience, Inc. ing rentang 04.07.2022 - 19.03.2025

Ringkesan rincian data analitis Aadi Bio (AADI)

- nilai saham lan prakiraan konsensus rega:

Bagan rega Aadi Bioscience|AADI - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Aadi Bioscience Inc|AADI - Nilai Perusahaan Nalika Diakuisisi Penuh

- informasi kapitalisasi buku:

Nilai Buku saben Saham Aadi Bioscience|AADI - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih aadibio.com|AADI - Aset Agregat Bisnis

- data utang lan likuiditas:

- statistik bathi lan rasio pasar:

AADI - Bathi pungkasan|Proyeksi bathi mangsa ngarep Aadi Bioscience|AADI - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Aadi Bioscience|AADI - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Aadi Bioscience Inc|AADI - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Aadi Bioscience|AADI - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan aadibio.com|AADI - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Aadi Bioscience

- data dodolan lan asil:

AADI - Pendapatan lan volume dodolan|Prakiraan volume dodolan Aadi Bioscience|AADI - Multiplikator P/S|Multiplikator Forward P/S Aadi Bioscience Inc

Ringkesan analitik perusahaan:Aadi Bioscience, Inc. AADI

Future sales volume determines expected revenue, serving as a fundamental benchmark for operating income. The calculation model offsets short-term volatility, revealing a sustainable trend in cash inflows. By analyzing the company's planned sales levels, an investor assesses the business's scaling potential. For Aadi Bioscience (AADI), this indicator reflects the commercial success of integrating the drug FYARRO into clinical protocols. Growth in this metric confirms the demand for targeted therapy for rare oncological diseases.

Pesaing langsung

Prakiraan pendapatan perusahaan Genmab A/S (GMAB)|EXEL (exelixis.com) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan NUVL (Nuvalent)|Prakiraan dodolan perusahaan Kymera Therapeutics, Inc.|IDEAYA Bio - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Enliven Corp|ORIC (ORIC Pharmaceuticals) - Volume dodolan mangsa ngarep perusahaan|RLAY: Prakiraan volume pendapatan perusahaan|NRIX (Nurix Therapeutics, Inc.) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Tyra Biosciences Inc TYRA|Prakiraan volume dodolan VSTM|Monte Rosa Corp - Prakiraan pendapatan perusahaan|Cullinan Therapeutics - Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan IMRX|CCCC: Volume dodolan mangsa ngarep perusahaan|Black Diamond Therapeutics, Inc. - Prakiraan volume pendapatan perusahaan|RPTX: Prakiraan volume dodolan|PMV Pharmaceuticals, Inc - Pendapatan mangsa ngarep perusahaan|KPTI (Karyopharm Therapeutics, Inc.) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Propanc Biopharma, Inc. PPCB|Prakiraan pendapatan perusahaan Bio Green Med Solution (BGMS)|ALRN (aileronrx.com) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan BPMC (Blueprint Medicines Corporation)|Prakiraan volume dodolan GlycoMimetics Inc. GLYC|SWTX - Prakiraan pendapatan perusahaan